Based on the Processa Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Processa Pharmaceuticals Inc is not available over the next 12 months. Processa Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Processa Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Processa Pharmaceuticals Inc’s stock price was USD 0.22. Processa Pharmaceuticals Inc’s stock price has changed by -18.33% over the past week, -48.70% over the past month and -85.58% over the last year.
No recent analyst target price found for Processa Pharmaceuticals Inc
No recent average analyst rating found for Processa Pharmaceuticals Inc
Company Overview Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. Read Less
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or ...Read More
Frequently Asked Questions About Processa Pharmaceuticals Inc (PCSA) Stock
Stock Target Advisor's fundamental analysis for Processa Pharmaceuticals Inc's stock is Very Bearish.
Unfortunately we do not have enough data on PCSA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PCSA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PCSA's stock to indicate if its overvalued.
The last closing price of PCSA's stock was USD 0.22.
The most recent market capitalization for PCSA is USD 1.31M.
Unfortunately we do not have enough analyst data on PCSA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Processa Pharmaceuticals Inc's stock.
As per our most recent records Processa Pharmaceuticals Inc has 10 Employees.
Processa Pharmaceuticals Inc's registered address is 7380 Coca Cola Drive, Hanover, MD, United States, 21076.
You can get more information about it from Processa Pharmaceuticals Inc's website at https://www.processapharmaceuticals.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Processa Pharmaceuticals Inc (PCSA) Stock
Stock Target Advisor's fundamental analysis for Processa Pharmaceuticals Inc's stock is Very Bearish.
Unfortunately we do not have enough data on PCSA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PCSA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PCSA's stock to indicate if its overvalued.
The last closing price of PCSA's stock was USD 0.22.
The most recent market capitalization for PCSA is USD 1.31M.
Unfortunately we do not have enough analyst data on PCSA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Processa Pharmaceuticals Inc's stock.
As per our most recent records Processa Pharmaceuticals Inc has 10 Employees.
Processa Pharmaceuticals Inc's registered address is 7380 Coca Cola Drive, Hanover, MD, United States, 21076.
You can get more information about it from Processa Pharmaceuticals Inc's website at https://www.processapharmaceuticals.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PCSA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
